» Articles » PMID: 34035116

Polyclonal Expansion of TCR Vbeta 21.3 CD4 and CD8 T Cells is a Hallmark of Multisystem Inflammatory Syndrome in Children

Abstract

Multiple Inflammatory Syndrome in Children (MIS-C) is a delayed and severe complication of SARS-CoV-2 infection that strikes previously healthy children. As MIS-C combines clinical features of Kawasaki disease and Toxic Shock Syndrome (TSS), we aimed to compare the immunological profile of pediatric patients with these different conditions. We analyzed blood cytokine expression, and the T cell repertoire and phenotype in 36 MIS-C cases, which were compared to 16 KD, 58 TSS, and 42 COVID-19 cases. We observed an increase of serum inflammatory cytokines (IL-6, IL-10, IL-18, TNF-α, IFNγ, CD25s, MCP1, IL-1RA) in MIS-C, TSS and KD, contrasting with low expression of HLA-DR in monocytes. We detected a specific expansion of activated T cells expressing the Vβ21.3 T cell receptor β chain variable region in both CD4 and CD8 subsets in 75% of MIS-C patients and not in any patient with TSS, KD, or acute COVID-19; this correlated with the cytokine storm detected. The T cell repertoire returned to baseline within weeks after MIS-C resolution. Vβ21.3+ T cells from MIS-C patients expressed high levels of HLA-DR, CD38 and CX3CR1 but had weak responses to SARS-CoV-2 peptides in vitro Consistently, the T cell expansion was not associated with specific classical HLA alleles. Thus, our data suggested that MIS-C is characterized by a polyclonal Vβ21.3 T cell expansion not directed against SARS-CoV-2 antigenic peptides, which is not seen in KD, TSS and acute COVID-19.

Citing Articles

TGFβ links EBV to multisystem inflammatory syndrome in children.

Goetzke C, Massoud M, Frischbutter S, Guerra G, Ferreira-Gomes M, Heinrich F Nature. 2025; .

PMID: 40074901 DOI: 10.1038/s41586-025-08697-6.


Cellular and soluble plasma immune markers at presentation in multisystem inflammatory syndrome in children and Kawasaki disease in South Africa: An observational study.

Abraham D, van Coller A, Tattersall M, Mohlake E, Yunis N, Webb K Medicine (Baltimore). 2025; 104(7):e41516.

PMID: 39961004 PMC: 11835083. DOI: 10.1097/MD.0000000000041516.


The complex landscape of immune dysregulation in multisystem inflammatory syndrome in children with COVID-19.

Guo J, Wang L Life Med. 2025; 3(4):lnae034.

PMID: 39872865 PMC: 11749780. DOI: 10.1093/lifemedi/lnae034.


Diagnostic Markers of Severe COVID-19 and Community-Acquired Pneumonia in Children From Southern India.

Damodar T, Lodha L, Suran S, Prabhu N, Jose M, Kinhal U Microbiol Immunol. 2025; 69(3):174-181.

PMID: 39812381 PMC: 7617320. DOI: 10.1111/1348-0421.13198.


Prognostic Value of Baseline Serum Pro-Inflammatory Cytokines in Severe Multisystem Inflammatory Syndrome in Children.

Bartha-Tatar A, Sinkovits G, Schnur J, Maraczi V, David M, Zsigmond B J Clin Med. 2024; 13(23).

PMID: 39685637 PMC: 11642126. DOI: 10.3390/jcm13237177.


References
1.
Hadjadj J, Castro C, Tusseau M, Stolzenberg M, Mazerolles F, Aladjidi N . Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun. 2020; 11(1):5341. PMC: 7578789. DOI: 10.1038/s41467-020-18925-4. View

2.
Bartsch Y, Wang C, Zohar T, Fischinger S, Atyeo C, Burke J . Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med. 2021; 27(3):454-462. PMC: 8315827. DOI: 10.1038/s41591-021-01263-3. View

3.
Tanaka Y, Hoshino-Negishi K, Kuboi Y, Tago F, Yasuda N, Imai T . Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases. Immunotargets Ther. 2020; 9:241-253. PMC: 7649223. DOI: 10.2147/ITT.S277991. View

4.
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P . Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395(10237):1607-1608. PMC: 7204765. DOI: 10.1016/S0140-6736(20)31094-1. View

5.
Bolotin D, Poslavsky S, Mitrophanov I, Shugay M, Mamedov I, Putintseva E . MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015; 12(5):380-1. DOI: 10.1038/nmeth.3364. View